The Lead Discovery Centre (LDC) and Cumulus Oncology are collaborating to enable the two organisations to accelerate the discovery and development of novel oncology therapies.
LDC contributes drug discovery expertise and a team of scientists with the ability to develop assets modulating a range of oncology targets derived from its large academic network. Cumulus Oncology brings a team of life science entrepreneurs with experience in translational oncology drug development, as well as oncologists, scientists and pharma sector business professionals.
This collaboration aims to develop a growing portfolio of small molecule and biological assets with medical and commercial potential. Each party provides targets and assets in the oncology area for collaboration and potential future company co-creation as well as bringing a wider access to funding partners and collaborators globally.
“We anticipate that joining forces with Cumulus Oncology will leverage early-stage novel oncology approaches from our research networks, turning these early-stage assets into true innovations in cancer research and therapies,” said Bert Klebl, CEO and CSO of the LDC.
“We are very much looking forward to working with our colleagues at LDC to the mutual benefit of both our organisations and ultimately to the benefit of the cancer research community, most especially, the patients dealing with a cancer diagnosis,” added Clare Wareing, Founder and CEO of Cumulus Oncology.
